Commodore Capital’s Third Harmonic Bio THRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-237,704
Closed -$2.45M 34
2024
Q4
$2.45M Sell
237,704
-1,122,865
-83% -$14M 0.18% 30
2024
Q3
$18.4M Sell
1,360,569
-184,857
-12% -$2.29M 1.15% 26
2024
Q2
$20.1M Buy
1,545,426
+295,426
+24% +$3.65M 1.37% 21
2024
Q1
$11.8M Buy
1,250,000
+543,294
+77% +$5.28M 0.79% 29
2023
Q4
$7.75M Sell
706,706
-993,294
-58% -$7.87M 0.68% 28
2023
Q3
$10.9M Buy
1,700,000
+706,706
+71% +$4.32M 1.27% 23
2023
Q2
$4.78M Hold
993,294
0.54% 23
2023
Q1
$4.09M Hold
993,294
0.62% 27
2022
Q4
$4.27M Sell
993,294
-25,275
-2% -$423K 0.64% 29
2022
Q3
$19.3M Buy
+1,018,569
New +$18.4M 3.11% 12

Other funds holding THRD

Commodore Capital's THRD Position: Q1 2025 in Review

Commodore Capital sold out of Third Harmonic Bio (THRD) in Q1 2025, closing a stake of 237,704 shares — an estimated $2.45M sold.

Commodore Capital first reported a position in THRD in Q3 2022 and held it in 10 quarters. The position peaked at $20.1M in Q2 2024. 99 funds tracked by Wall St. Rank hold THRD as of Q1 2025.

  • Commodore Capital reported no remaining Third Harmonic Bio position as of Q1 2025 after selling out during the quarter.
  • Commodore Capital sold 237,704 Third Harmonic Bio shares in Q1 2025, an estimated $2.45M.
  • Commodore Capital first reported a position in Third Harmonic Bio in Q3 2022 and held it in 10 quarters.
  • Commodore Capital's Third Harmonic Bio position peaked at $20.1M in Q2 2024.
  • 99 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q1 2025.

Based on Commodore Capital's 13F filing for Q1 2025, filed 15 May 2025.